FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol

Monte S. Buchsbaum, M. Mehmet Haznedar, Jonathan Aronowitz, Adam M. Brickman, Randall E. Newmark, Rachel Bloom, Jesse Brand, Kim E. Goldstein, Desmond Heath, Meghan Starson, Erin A. Hazlett

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

We acquired Positron emission tomography with 18-F-deoxyglucose (FDG-PET) and anatomical MRI in 30 never-previously medicated psychotic adolescents (ages 13-20). (FDG-PET) was obtained at baseline and after 8-9 weeks of a randomized double-blind trial of either olanzapine or haloperidol. Neuropsychological tests of executive function were also obtained. Patients carried out the serial verbal learning task, a modification of the California Verbal Learning Test, during the uptake of the FDG. PET scans were coregistered with spoiled gradient MRI (TR = 24, TE = 5, flip angle 40°, slice thickness 1.2 mm, field of view 230 mm) for accurate anatomical identification of regions of interest traced on the MRI. Twenty-two of the thirty patients completed the second PET and clinical evaluation. Individuals treated with olanzapine increased relative metabolic rates in the frontal lobe more than the occipital lobe while patients treated with haloperidol failed to increase frontal metabolic rates and did not show an anteroposterior gradient in medication response. Haloperidol increased striatal metabolic rate more than olanzapine. Both drugs increased thalamic metabolic rates and this increase was significantly larger in younger (age 13-15) than older (16-21) patients.

Original languageEnglish
Pages (from-to)293-305
Number of pages13
JournalSchizophrenia Research
Volume94
Issue number1-3
DOIs
StatePublished - Aug 2007
Externally publishedYes

Bibliographical note

Funding Information:
The project data collection was partly supported by Eli Lilly and Company.

Funding Information:
Dr. Richard Pico contributed to the initial planning of the project. Dr. Eileen DiFrancesco assisted in the recruitment of patients. This research was supported by a grant from the National Intsitute of Mental Health, Anatomy and function of the thalamus in schizophrenia MH60023, and by General Clinical Research Center CRC grant # 5-M01 RR00071. The data collection was supported by an investigator-initiated grant from Eli Lilly and Company.

Funding Information:
This work was supported by an investigator-initiated grant from Eli Lilly, and by grants from the National Center for Research Resources (M01-RR-00071), and the National Institute of Mental Health (MH60023, MH56489, MH60384S). The study was designed by the first author, and elements of the data analysis and presentation supported by these other sources. The authors have no financial interest in the project outcome.

Funding Information:
This pharmacoimaging work was supported by an investigator-initiated grant from Eli Lilly, and by grants from the National Center for Research Resources (M01-RR-00071), and the National Institute of Mental Health for the study of schizophrenia (MH60023, MH56489, MH60384S). The study was designed by the first author and elements of the data collection, analysis and presentation supported by these sources. The authors worked together on the analysis of data. The funding sources all favored the authors in their efforts to report the scientific findings and we appreciate their flexibility and patience.

Keywords

  • Early onset
  • Hypofrontality
  • Neuroleptic
  • Schizophrenia
  • Striatum
  • Thalamus

Fingerprint

Dive into the research topics of 'FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol'. Together they form a unique fingerprint.

Cite this